VIASKIN Peanut patch
The VIASKIN Peanut patch delivers controlled amounts of peanut protein through intact skin to desensitize allergic children. DBV is developing the 250 µg patch to reduce the severity of reactions on accidental exposure.
Also known as: VIASKIN Peanut, DBV712, Viaskin
VIASKIN Peanut patch forecasting benchmarks
1 benchmarkIndications studied
Developed by
About VIASKIN Peanut patch
What is VIASKIN Peanut patch?
The VIASKIN Peanut patch delivers controlled amounts of peanut protein through intact skin to desensitize allergic children. DBV is developing the 250 µg patch to reduce the severity of reactions on accidental exposure. It is a epicutaneous immunotherapy (skin patch) developed by DBV Technologies.
What does VIASKIN Peanut patch target?
VIASKIN Peanut patch's mechanism is summarized above; see the linked trial readouts for details.
How well do AI models predict VIASKIN Peanut patch trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.